RGT-61159 for Cancer
Trial Summary
Will I have to stop taking my current medications?
The trial protocol does not specify if you must stop taking your current medications. However, you cannot have had chemotherapy within 14 days, certain other treatments within specific time frames, or ongoing infections requiring treatment before starting the trial.
What data supports the effectiveness of the drug RGT-61159 for cancer?
What makes the drug RGT-61159 unique for cancer treatment?
What is the purpose of this trial?
Phase 1 study to evaluate safety, tolerability and anti-tumor activity of RGT-61159 in patients with ACC or CRC
Eligibility Criteria
Adults with Adenoid Cystic Carcinoma (ACC) or Colorectal Cancer (CRC) that has come back or hasn't responded to treatment can join this trial. Specific details about who can and cannot participate are not provided, but typically these would include health status and prior treatments.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Dose Escalation
Participants receive escalating doses of RGT-61159 to determine the optimal dose
Dose Expansion
Participants receive RGT-61159 at the optimized dose to further assess safety and efficacy
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- RGT-61159
RGT-61159 is already approved in United States for the following indications:
- Adenoid cystic carcinoma (ACC)
- Colorectal cancer (CRC)
Find a Clinic Near You
Who Is Running the Clinical Trial?
Rgenta Therapeutics Inc
Lead Sponsor